Skip to main content
Top
Published in: Annals of Hematology 2/2004

01-02-2004 | Original Article

Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients

Authors: S. Ziegler, E. Alt, M. Brunner, W. Speiser, E. Minar

Published in: Annals of Hematology | Issue 2/2004

Login to get access

Abstract

Recently it was shown that inflammation adversely influences results obtained from the platelet function analyzer system, PFA-100, hypothesizing that inflammation could confound interpretation of platelet function results. We investigated the clinical relevance of these results in patients with peripheral arterial occlusive disease (PAOD), with and without signs of systemic inflammation. In 98 PAOD patients, all treated with acetyl-salicylic acid (ASA), we obtained PFA-100 values upon stimulation with epinephrine. C-reactive protein (CRP) values were investigated as indicator for systemic inflammation. Mean CRP levels were elevated in 23 patients (23%). There was no difference of mean PFA-100 results between patients with elevated CRP levels and those without. Our results indicate that the effect of ASA on platelet aggregation, as measured by the PFA-100, is not relevantly influenced in PAOD patients with elevated CRP.
Literature
1.
go back to reference Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E et al (2000) Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 36:110–114CrossRefPubMed Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E et al (2000) Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 36:110–114CrossRefPubMed
2.
go back to reference Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T et al (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145:51–60CrossRefPubMed Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T et al (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145:51–60CrossRefPubMed
3.
go back to reference Li-Saw-Hee FL, Blann AD, Lip GJ (2000) Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic arterial fibrillation. Stroke 31:828–833PubMed Li-Saw-Hee FL, Blann AD, Lip GJ (2000) Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic arterial fibrillation. Stroke 31:828–833PubMed
4.
go back to reference Isaka N, Tanigawa T, Nishikawa M, Nakano T (1998) High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy. Nippon Rinsho 56:2624–2629PubMed Isaka N, Tanigawa T, Nishikawa M, Nakano T (1998) High shear stress induced platelet aggregation (h-SIPA) and effects of antiplatelet therapy. Nippon Rinsho 56:2624–2629PubMed
5.
go back to reference Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B (2000) Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111:1250–1252CrossRefPubMed Homoncik M, Blann AD, Hollenstein U, Pernerstorfer T, Eichler HG, Jilma B (2000) Systemic inflammation increases shear stress-induced platelet plug formation measured by the PFA-100. Br J Haematol 111:1250–1252CrossRefPubMed
6.
go back to reference Gralnik HR, McKeown LP, Wilson OM, Williams SB, Elin RJ (1989) Von Willebrand factor release induced by endotoxin. J Laborat Clin Medicine 113:118–122 Gralnik HR, McKeown LP, Wilson OM, Williams SB, Elin RJ (1989) Von Willebrand factor release induced by endotoxin. J Laborat Clin Medicine 113:118–122
7.
go back to reference Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481–2485CrossRefPubMed Ridker PM, Stampfer MJ, Rifai N (2001) Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285:2481–2485CrossRefPubMed
8.
go back to reference Langlois M, Duprez D, Delanghe J, Buyzere M, Clement DL (2001) Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 103:1863–1868PubMed Langlois M, Duprez D, Delanghe J, Buyzere M, Clement DL (2001) Serum vitamin C concentration is low in peripheral arterial disease and is associated with inflammation and severity of atherosclerosis. Circulation 103:1863–1868PubMed
9.
go back to reference Rossi E, Biasucci LM, Citterio F, Pellicioni S, Monaco C, Ginnetti F, et al (2002) Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 105:800–803CrossRefPubMed Rossi E, Biasucci LM, Citterio F, Pellicioni S, Monaco C, Ginnetti F, et al (2002) Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. Circulation 105:800–803CrossRefPubMed
10.
go back to reference Ortel T, James AH, Thames EH, Moore KD, Greenberg CS (2000) Assessment of primary hemostasis by PFA-100 Analysis in a tertiatry care centre. Thromb Haemost 84:93–97PubMed Ortel T, James AH, Thames EH, Moore KD, Greenberg CS (2000) Assessment of primary hemostasis by PFA-100 Analysis in a tertiatry care centre. Thromb Haemost 84:93–97PubMed
11.
go back to reference Von Pape KW, Aland E, Bohner J (2000) Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 98:295–299CrossRefPubMed Von Pape KW, Aland E, Bohner J (2000) Platelet function analysis with PFA-100 in patients medicated with acetylsalicylic acid strongly depends on concentration of sodium citrate used for anticoagulation of blood sample. Thromb Res 98:295–299CrossRefPubMed
12.
go back to reference Albert MA, Ridker PM (1999) The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1:99–104PubMed Albert MA, Ridker PM (1999) The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1:99–104PubMed
13.
go back to reference McKenzie M, Gurbel PA, Levine DJ, Serebruany VL (1999) Clinical Utility of available methods for determining platelet function. Cardiology 92:240–247CrossRefPubMed McKenzie M, Gurbel PA, Levine DJ, Serebruany VL (1999) Clinical Utility of available methods for determining platelet function. Cardiology 92:240–247CrossRefPubMed
14.
go back to reference Camici M (2002) C-reactive protein, atherosclerosis and cardiovascular disease. An update. Minerva Cardioangiol 50:327–331PubMed Camici M (2002) C-reactive protein, atherosclerosis and cardiovascular disease. An update. Minerva Cardioangiol 50:327–331PubMed
15.
go back to reference Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26:517–538PubMed Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al (1997) Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 26:517–538PubMed
16.
go back to reference Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of asoirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83:316–321PubMed Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of asoirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83:316–321PubMed
17.
go back to reference Silva JA, White CJ (2002) Plaque instability in peripheral vessels. Prog Cardiovasc Dis 44:429–436CrossRefPubMed Silva JA, White CJ (2002) Plaque instability in peripheral vessels. Prog Cardiovasc Dis 44:429–436CrossRefPubMed
18.
go back to reference Van Genderen PJ, van Vliet HH, Prins FJ, van de Moesdijk D, van Strik R, Zijlstra FJ, Budde U, et al (1997) Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 75:215–220PubMed Van Genderen PJ, van Vliet HH, Prins FJ, van de Moesdijk D, van Strik R, Zijlstra FJ, Budde U, et al (1997) Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 75:215–220PubMed
19.
go back to reference Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B (2001) Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men. Atherosclerosis 155:389–393CrossRefPubMed Pernerstorfer T, Eichler HG, Stohlawetz P, Speiser W, Jilma B (2001) Effects of heparin and aspirin on circulating P-selectin, E-selectin and von Willebrand Factor levels in healthy men. Atherosclerosis 155:389–393CrossRefPubMed
20.
go back to reference Kaplan RC, Frishman WH (2001) Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 3:326–332PubMed Kaplan RC, Frishman WH (2001) Systemic inflammation as a cardiovascular disease risk factor and as a potential target for drug therapy. Heart Dis 3:326–332PubMed
21.
go back to reference Cheng TO (1999) Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin Cardiol 22:A27 Cheng TO (1999) Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clin Cardiol 22:A27
22.
go back to reference Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, et al (2002) Prevention of inflammation-induced endothelial dysfunction. A novel vasculo-protective action of aspirin. Circulation 105:2600–2604CrossRefPubMed Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, et al (2002) Prevention of inflammation-induced endothelial dysfunction. A novel vasculo-protective action of aspirin. Circulation 105:2600–2604CrossRefPubMed
23.
go back to reference Guarnieri G (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145:51–60CrossRefPubMed Guarnieri G (1999) Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145:51–60CrossRefPubMed
Metadata
Title
Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients
Authors
S. Ziegler
E. Alt
M. Brunner
W. Speiser
E. Minar
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 2/2004
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0789-8

Other articles of this Issue 2/2004

Annals of Hematology 2/2004 Go to the issue